Med. praxi 2012; 9(6-7): 274-276
News in vaccination against pneumococcal infections in adults
- Katedra epidemiologie, Fakulta vojenského zdravotnictví UO, Hradec Králové
More risk factors for the emergence and development of pneumococcal disease, especially invasive forms and community-acquired
pneumonia are present in adults, unlike children. The main risk factor is age, incidence of chronic diseases and smoking. Current possibilities
of adult vaccination were expanded to include a new indication for using 13valent conjugate pneumococcal vaccine for persons
aged 50 years and older. Conjugate vaccine showed high immunogenicity and good safety profile, both in those aged 50 years and the
elderly aged over 70 years of age. The conjugate vaccine achieved no worse results of functional antibody titers against all 12 serotypes
and for a number of serotypes was achieved statistically significantly higher titers of antibodies in conjugate vaccine compared with
23valent polysaccharide vaccine. A single dose of PCV13 may be recommended for all persons ≥ 50 years regardless of previous vaccination
against pneumococcus, especially for groups at risk and older adults.
Keywords: pneumococcus, conjugate vaccine, pneumococcal disease, vaccination
Published: August 1, 2012 Show citation
References
- World Health Organization. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008; 83(42): 373-384.
Go to PubMed... - Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010; 59(34): 1102-1106.
- Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005; 192(3): 377-386.
Go to original source... Go to PubMed... - Center for Disease Control and Prevention. 2010. Active Bacterial Corer Surveillance Report, Emerging INfections Program Network, Streptococcus pneumoniae, 200 9. Available from: http://www.cdc.gov./abcs/reports-findings/survreports/spneu09.pdf.
- Motlová J, Beneš Č, Křížová P. Invazivní pneumokoková onemocnění v České republice v roce 200 9. Zprávy EM (SZÚ Praha). 2010; 19(3): 68-77.
- Skoczyńska A, Sadowy E, Bojarska K, Strzelecki J, Kuch A, Gołębiewska A, et al. The current status of invasive pneumococcal disease in Poland. Vaccine. 2011; 29(11): 2199-2205. Go to original source... Go to PubMed...
- Centers for Disease Control and Prevention (CDC). Pneumococcal Disease. In: Epidemiology and Prevention of Vaccine-Preventable Diseases, "Pink Book". 10th edition 2007; 12: 257-270.
- Motlová J, Kozáková J, Křížová P. Invazivní pneumokoková onemocnění v České republice v roce 2010. Zprávy EM (SZÚ Praha). 2011; 20(2): 64-69.
- Křížová P. Invazivní pneumokoková onemocnění v ČR - výsledky surveillance 2011. Přednáška na sympóziu Prevence pneumokokových onemocnění dostupnými konjugovanými vakcínami, Praha, 2012.
- EMA. CHMP Variation Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001104/WC500119784.pdf. (Access 23.2.2012).
- Marešová V. Riziko pneumokokové pneumonie u dospělých a jeho možná prevence. In: Sborník abstrakt. VII Hradecké vakcinologické dny. Praha: ČVS ČLS JEP; 2011: 31. Go to original source...